Insulin Degludec Aspart: The First Co-formulation of Insulin Analogues

Diabetes Therapy

Volumn 5, Issue 1, 2014, Pages 65-72

  Kalra, Sanjay ^a  

^a Bharti Hospital and Bharti Research Institute of Diabetes and Endocrinology   (India)

Author keywords

Diabetes; Insulin aspart; Insulin degludec

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN DEGLUDEC; INSULIN DERIVATIVE; INSULIN GLULISINE; INSULIN LISPRO; MEGLITINIDE; METFORMIN; SULFONYLUREA DERIVATIVE;

BLOOD GLUCOSE MONITORING; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT;

EID: 84926006558     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-014-0067-x     Document Type: Review

References (25)

1. 1chieve study. Diabetes Res Clin Pract. 2013;101(Suppl 1):S4–14.
2. Davidson JA, Liebl A, Christiansen JS, et al. Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: a meta-analysis. Clin Ther. 2009;31(8):1641–51.
3. Kalra S. Insulin degludec: a significant advancement in ultralong-acting basal insulin. Diabetes Ther. 2013;4(2):167–73.
4. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55:1577–96.
5. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2009;32:193–203.
6. Leiter L, Yale JF, Chiasson J, et al. Assessment of the impact of fear of hypoglycaemic episodes on glycaemic and hypoglycaemia management. Can J Diabetes. 2005;29:186–92.
7. Peyrot M, Barnett A, Meneghini L, Schumm-Draeger P. Insulin adherence behaviors and barriers in the multi-national global attitudes of patients and physicians in insulin therapy (GAPP) study. Diabetic Med. 2012;29:682–9.
8. Vijan S, Hayward RA, Ronis DL, et al. Brief report: the burden of diabetes therapy: implications for the design of effective patient-centered treatment regimens. J Gen Intern Med. 2005;20:479–82.
9. Peyrot M, Rubin RR, Kruger D, Travis LB. Correlates of insulin injection omission. Diabetes Care. 2010;33:240–5.
10. Jonassen I, Havelund S, Hoeg-Jensen T, et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res. 2012;29:2104–14.
11. Heise T, Nosek L, Hastrup H, et al. IDegAsp shows distinct prandial and basal glucose-lowering effects at steady state in subjects with type 1 diabetes. Diabetes. 2013;62(suppl 1):A235 (abstract 926-P).
12. Zinman B, Philis-Tsimikas A, Cariou B, Handelsman Y, Rodbard HW, Johansen T, et al. Insulin degludec versus insulin glargine in insulin-naïve patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial [BEGIN Once Long]. Diabetes Care. 2012;35:2464–71.
13. Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L, et al. Insulin degludec, ultra long acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes [BEGIN Basal-Bolus Type 1]: a phase 3, randomised, open-label, treat-to target non-inferiority trial. Lancet. 2012;379(9825):1489–97.
14. Garber AJ, King AB, Del Prato S, Sreenan S, Balci MK, Muñoz-Torres M, et al. Insulin degludec, ultra-longacting basal insulin, versus insulin glargine in basalbolus treatment with mealtime insulin aspart in type 2 diabetes [BEGIN Basal-Bolus Type 2]: a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379(9825):1498–507.
15. Mathieu C, Hollander P, Miranda-Palma B, Cooper J, Franek E, Russell-Jones D, et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes [BEGIN: Flex T1]: a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab. 2013;98(3):1154–62.
16. Meneghini L, Atkin SL, Gough SC, Raz I, Blonde L, Shestakova M, et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel group, treat-to-target trial in people with type 2 diabetes. Diabetes Care. 2013;36(4):858–64.43.
17. Hirsch IB, Bode B, Courreges JP, Dykiel P, Franek E, Hermansen K, et al. Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial. Diabetes Care. 2012;35:2174–81.
18. Heise T, Tack CJ, Cuddihy R, Davidson J, Gouet D, Liebl A, et al. A new-generation ultra-long acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial. Diabetes Care. 2011;34(3):669–74.
19. Onishi Y, Ono Y, Rabøl R, Endahl L, Nakamura S. Superior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial. Diabetes Obes Metab. 2013;15(9):826–32.
20. Fulcher G, Bantwal G, Christiansen JS, Andersen T, Mersebach H, Niskanen LK, et al. Superior FPG control and reduced hypoglycaemia with IDegAsp vs BIAsp 30 in adults with type 2 diabetes mellitus inadequately controlled on pre/self-mixed insulin: a randomised phase 3 trial. Poster presented at EASD 2013 Barcelona. Poster no 1044; 2013.
21. Christiansen JS, Chow FCC, Choi DS, Taneda S, Hirao K. Superior FPG control and less nocturnal hypoglycaemia with IDegAsp vs BIAsp 30 in Asian subjects poorly controlled on basal or pre/self-mixed insulin: randomized phase 3 trial. Poster presented at EASD 2013 Barcelona. Poster No 1045; 2013.
22. Liebl A, Davidson J, Mersebach H, Dykiel P, Tack CJ, Heise T. A novel insulin combination of insulin degludec and insulin aspart achieves a more stable overnight glucose profile than insulin glargine: results from continuous glucose monitoring in a proof-of-concept trial. J Diabetes Sci Technol. 2013;7(5):1328–36.
23. Niskanen L, Leiter LA, Franek E, Weng J, Damci T, Muñoz-Torres M, et al. Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial. Eur J Endocrinol. 2012;167(2):287–94.
24. Ryzodeg® Summary of product characteristics (SmPC). Novo Nordisk A/S. Bagsværd, Denmark. 2012.
25. Thomas P, Stefan K, Sigrid D, Harald K, Carsten R. The distinct prandial and basal pharmacodynamics of IDegAsp observed in younger adults are preserved in elderly subjects with type 1 diabetes. In: Poster presented at 73rd American Diabetes Association meeting Chicago, June 21–25, Poster no 933 P; 2013.